Cargando…

Precision medicine approaches for diabetic kidney disease: opportunities and challenges

The prevalence of end-stage kidney disease (ESKD) continuously increases worldwide. The increasing prevalence parallels the growth in the number of people with diabetes, which is the leading cause of ESKD. Early diagnosis of chronic kidney disease (CKD) in patients with diabetes and appropriate inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tye, Sok Cin, Denig, Petra, Heerspink, Hiddo J L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216727/ https://www.ncbi.nlm.nih.gov/pubmed/34153985 http://dx.doi.org/10.1093/ndt/gfab045

Ejemplares similares

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
por: Mol, Peter G. M., et al.
Publicado: (2018)

A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores
por: Idzerda, Nienke M. A., et al.
Publicado: (2021)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients
por: Sokooti, Sara, et al.
Publicado: (2022)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness
por: Seymour, Christopher W., et al.
Publicado: (2017)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

No significant association of type 2 diabetes‐related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives
por: Martono, Doti P., et al.
Publicado: (2019)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study
por: Apperloo, Ellen M., et al.
Publicado: (2018)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Disease Biomarkers for Precision Medicine: Challenges and Future Opportunities
por: Wang, Edwin, et al.
Publicado: (2017)

Evolutionary Approaches to Combat Antibiotic Resistance: Opportunities and Challenges for Precision Medicine
por: Merker, Matthias, et al.
Publicado: (2020)

Precision medicine in human heart modeling: Perspectives, challenges, and opportunities
por: Peirlinck, M., et al.
Publicado: (2021)

When drug treatments bias genetic studies: Mediation and interaction
por: Schmidt, Amand F., et al.
Publicado: (2019)

Challenges and opportunities for precision medicine in neurodevelopmental disorders
por: Chen, George T., et al.
Publicado: (2022)

Opportunities and challenges of 5G network technology toward precision medicine
por: Kang, Chia Chao, et al.
Publicado: (2023)

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting
por: Bakker, Elisabeth, et al.
Publicado: (2021)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data
por: Belur Nagaraj, Sunil, et al.
Publicado: (2020)

Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine
por: Yu, Yiqi, et al.
Publicado: (2021)

Precision medicine in severe pediatric asthma: opportunities and challenges
por: Vijverberg, Susanne J.H., et al.
Publicado: (2020)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Precision Medicine Approaches to Diabetic Kidney Disease: Personalized Interventions on the Horizon
por: Nageeta, FNU, et al.
Publicado: (2023)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Epilepsy in the mTORopathies: opportunities for precision medicine
por: Moloney, Patrick B, et al.
Publicado: (2021)

Application of precision medicine in clinical routine in haematology—Challenges and opportunities
por: Wästerlid, Tove, et al.
Publicado: (2022)

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists
por: van Baar, Michaël J. B., et al.
Publicado: (2019)

Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020
por: Bakker, Elisabeth, et al.
Publicado: (2023)

Gastric Intestinal Metaplasia: Challenges and the Opportunity for Precision Prevention
por: Tjandra, Douglas, et al.
Publicado: (2023)

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges
por: Bukłaho, Patrycja Aleksandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_spr2pm2nctt2t9otee8k8l745n